Trick or Trade- Prohost Biotech - Exclusive Biotech Research

Category: Trick or Trade

Why the Current Interest in Ventyx Biosciences

The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus We like the fact that Ventyx Biosciences ( VTYX ) is not just focusing on developing innovative oral Drugs for people living with autoimmune and inflammatory disorders, but also...

March 7, 2023

Encouraging News from Hoth Therapeutics and Kintor Pharmaceutical Ltd About Treating Acne and Alopecia

Hoth Therapeutics Hoth Therapeutics ( HOTH ) announced that its product, HT-003, has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 ( TLR2 ), which happens...

July 14, 2021

Our Eyes Are on Reata Pharmaceuticals Today

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals ( RETA ) announced a setback of its chronic kidney disease product known as bardoxolone. The failure of this drug occurred after Reata's product Skyclaris was FDA approved for the treatment of Friedrich's...

May 25, 2023

The U.S. FDA Accepts Exelixis sNDA of CABOMETYX® for Priority Review

Exelixis sNDA Accepted by the US FDA for CABOMETYX ® The U.S. Food and Drug Administration ( FDA ) accepted Exelixis ( EXEL ) supplemental New Drug Application ( sNDA ) for CABOMETYX ® (cabozantinib) as a treatment for patients...

August 6, 2021

Gain Therapeutics: A Biotech with Promising Treatments for Neurodegenerative Diseases and a Note from Prohost Biotech

Gain Therapeutics Inc in the News Gain Therapeutics, Inc. ( GANX ) announced today topline data from its study conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators ( STARs...

September 8, 2021

Immunovent, Altimmune and Soleno: A Summary of Three Firms We Believe Have Promising Technologies and Treatments

Immunovent, Altimmune & Soleno In addition to Vertex ( VRTX ) , Crispr Therapeutics ( CRSP ) and Acturus Therapeutics ( ARCT ) , the following summaries are of three firms we believe have promising Products 1. Immunovent The phase...

December 27, 2023

Why Jounce Therapeutics Stock is Outperforming Today

Jounce Therapeutics Jounce Therapeutics ( JNCE ) is a clinical-stage immunotherapy company developing therapies enabling the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce has ongoing multiple development stage programs while simultaneously...

September 14, 2021

Vertex Pharmaceuticals Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Pharmaceuticals Updates Vertex Pharmaceuticals ( VRTX ) announced multiple program updates ahead of the upcoming investor meetings in January, including the 42 Annual J.P. Morgan Healthcare Conference, which took place on January 8, 2024. From Vertex Pharmaceuticals Reshma Kewalramani,...

January 9, 2024

OKYO Pharma Limited: Another Ophthalmology Firm with Promising Eye Treatment

Improving eyesight is speeding towards treating devastating eye diseases from the Retina in the back of the eye to the cornea on the front surface of the eye. As we wrote in Prohost Letter #457 , the current biotechnology revolution...

January 11, 2024

The Time Has Come to Present Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc Mirum Pharmaceuticals Inc ( MIRM ) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Maralixibat, is Mirum Pharmaceuticals lead product candidate. The product...

September 27, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024